- Clinical Trials
- Research News
- Industry Trends
- Agency Actions
- Drug Safety Issues
- Approvals, Launches, & New Indications
- Health Care Reform
Launch Set for Weight-Loss Drug Lorcaserin (Belviq)
Product available June 11 for obese and overweight patients (June 7)
Launch plans have been announced for lorcaserin (Belviq; Arena Pharmaceuticals/Eisai Inc.). The weight-loss drug will be available to patients by prescription in U.S. pharmacies beginning June 11.
Belviq (lorcaserin) is approved for use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, or type 2 diabetes). The recommended dosage is 10 mg twice daily.
The safety and efficacy of co-administration of lorcaserin with other products intended for weight loss and the effect of lorcaserin on cardiovascular morbidity and mortality have not been established.
Lorcaserin is believed to decrease food consumption and to promote satiety by selectively activating serotonin 2C receptors in the brain. The drug’s exact mechanism of action is unknown.
Source: Arena Pharmaceuticals; June 7, 2013.